Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082797 · ClinicalTrials.gov registry record · Phase 2
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00082797 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 36 participants.
The verdict
NCT00082797, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop tumor cells from dividing so they stop growing or die. Leucovorin may decrease side effects caused by high-dose methotrexate. PURPOSE: This phase II trial is studying how well giving high-dose methotrexate together with leucovorin works in treating patients with newly diagnosed glioblastoma multiforme.
Interventions
- DRUG leucovorin calcium
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082797
The ClinicalTrials.gov registry entry for NCT00082797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which leucovorin calcium is the first listed.
NCT00082797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082797 about?
NCT00082797 is a clinical study titled "High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop tumor cells from dividing so they stop growing or die. Leucovorin may decrease side effects caused by high-dose methotrexate. PURPOSE: This phase II trial is studying how well giving high-dose methotrexate t...
What is the current status of trial NCT00082797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-07-12.
What interventions are being tested in trial NCT00082797?
The interventions under investigation include: leucovorin calcium (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00082797?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.